126 related articles for article (PubMed ID: 1610270)
21. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
22. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
23. Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload.
Zuppinger K; Molinari B; Hirt A; Imbach P; Gugler E; Tönz O; Zurbrügg RP
Helv Paediatr Acta; 1979; 34(3):197-207. PubMed ID: 500381
[TBL] [Abstract][Full Text] [Related]
24. Treatment of primary hemochromatosis with deferoxamine.
Young N; Henry W; Nienhuis AW
JAMA; 1979 Mar; 241(11):1152-4. PubMed ID: 762769
[No Abstract] [Full Text] [Related]
25. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
26. [Intensive intravenous chelation in thalassemic patients with iron overload].
Di Gregorio F; Leonardi C; Sciuto C; Cannella A; Pizzarelli G
Minerva Pediatr; 1998 Mar; 50(3):81-5. PubMed ID: 9676102
[TBL] [Abstract][Full Text] [Related]
27. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
28. Neonatal hemochromatosis: failure of deferoxamine therapy.
Jonas MM; Kaweblum YA; Fojaco R
J Pediatr Gastroenterol Nutr; 1987; 6(6):984-8. PubMed ID: 3681586
[TBL] [Abstract][Full Text] [Related]
29. High-dose intravenous chelation therapy with deferoxamine.
Cohen A; Mizanin J; Schwartz E
Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
[No Abstract] [Full Text] [Related]
30. [Post-transfusion hemochromatosis. Results of a study carried out in Blood Transfusion Centers. Analysis of 15 cases treated with subcutaneous perfusion of Desferal. Working group "Transfusion Techniques and Therapeutics"].
Jaulmes D; Quarre MC; Audat F; Gaonach MJ
Transfus Clin Biol; 1994; 1(1):55-64. PubMed ID: 8186855
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
[TBL] [Abstract][Full Text] [Related]
32. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Tsironi M; Deftereos S; Andriopoulos P; Farmakis D; Meletis J; Aessopos A
Eur J Haematol; 2005 Jan; 74(1):84-5. PubMed ID: 15613114
[TBL] [Abstract][Full Text] [Related]
33. Liver iron overload and liver fibrosis in thalassemia.
Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
[No Abstract] [Full Text] [Related]
34. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
35. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
[TBL] [Abstract][Full Text] [Related]
36. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
Bachelot C; Plantaz D
Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
38. Treatment of iron overload.
Cohen A; Witzleben C; Schwartz E
Semin Liver Dis; 1984 Aug; 4(3):228-38. PubMed ID: 6091277
[No Abstract] [Full Text] [Related]
39. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
Kobayashi M; Yano K; Fujisawa S
Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
[TBL] [Abstract][Full Text] [Related]
40. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
